Stock Analiz

Altimmune, Inc. ALT

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.65Market cap $320M
Open the interactive analysis →

Altimmune, Inc. (ALT) is a healthcare company listed in the US with a market value of about $320M. In fiscal year 2025 it had revenue of $41000 and net income of -$88M, a net margin of -214861.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -65% a year, a 5-year average ROIC of -45%.

About Altimmune

Altimmune is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2016 to $41000 in 2025, a decline of about 38.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 162029% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7,807.0
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-32.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)105.0%
Revenue growth (5 yrs, per year)-65.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-117700.0%
ROIC (5-yr avg.)-44.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$41000$20000$426000-$68000$4M$8M$6M$10M$11M$3M
Net income-$88M-$95M-$88M-$85M-$97M-$49M-$21M-$39M-$46M-$11M
Free cash flow-$68M—-$76M-$63M-$90M-$35M-$10M-$10M-$20M-$6M
EPS (diluted)$-1.00$-1.34$-1.66$-1.81$-2.35$-1.91$-1.60$-15.16$-118.91$87.47
Net margin-214900.0%-475300.0%-20762.2%124600.0%-2201.6%-599.2%-353.7%-379.2%-432.3%-342.6%
ROIC-36.0%-65.1%-38.9%-45.8%-37.9%-21.5%-43.6%-73.7%-105.4%-33.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $16.33, 893% above the current price; targets range from $11.00 to $26.00; the consensus rating is “Strong buy”; expected EPS is $-0.63 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Altimmune pay a dividend?

Not currently.

Is Altimmune a good stock to buy?

We do not give buy or sell advice. Altimmune scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.